Objective-Vascular calcification which refers to ectopic mineralization in vascular cells is associated with several conditions, such as chronic kidney disease, atherosclerosis, and diabetes mellitus. Estrogen-related receptor (ERR)γ is a member of the orphan nuclear receptor superfamily, which plays diverse roles in regulating homeostatic and metabolic processes. However, the role of ERRγ in vascular calcification has not been investigated to date. The aim of the present study was to examine the role of ERRγ in vascular calcification. Approach and Results-Vascular calcification was induced by treating rat aortic vascular smooth muscle cells with calcification medium. ERRγ expression in vascular smooth muscle cells was induced during calcification mediuminduced vascular calcification. Adenovirus-mediated overexpression of ERRγ in vascular smooth muscle cells resulted in the upregulation of the expression of osteogenic genes, including runt-related transcription factor 2, osteopontin, and Msx2, and the downregulation of α-smooth muscle actin. Adenovirus-mediated overexpression of ERRγ induced bone morphogenetic protein 2 (BMP2) expression, leading to increased phosphorylation of the intracellular BMP2 effector proteins SMAD1/5/8. Collectively, these data suggested that ERRγ promotes dedifferentiation of vascular smooth muscle cells to an osteogenic phenotype during the vascular calcification process. Inhibition of endogenous ERRγ expression or activity using a specific siRNA or the selective inverse agonist GSK5182 attenuated vascular calcification and osteogenic gene expression in vitro and in vivo. 14 In a recent study, pharmacological inhibition of BMP signaling inhibited atheroma development and vascular calcification in high fat diet-fed low-density lipoprotein receptor −/− mice, suggesting a potential benefit of BMP inhibition in the treatment of vascular calcification. 8 The development of novel agents against these targets with the capacity to modulate signaling pathways would be beneficial for the treatment of patients with atherosclerosis and vascular calcification.
V ascular calcification is a major contributing factor to morbidity and mortality in patients with atherosclerosis, chronic kidney disease, and diabetes mellitus. [1] [2] [3] Vascular calcification is an actively regulated process of matrix mineral metabolism similar to the process of bone formation that results in the deposition of calcium phosphate in the arterial wall. 4, 5 This phenomenon includes the dedifferentiation or transformation of vascular smooth muscle cells (VSMCs) to an osteogenic phenotype in the setting of chronic kidney disease, diabetes mellitus, aging, or inflammation. 3 The induction of an osteogenic phenotype is characterized by an increase in the levels of osteogenic markers in the vascular wall, including runt-related transcription factor 2 (Runx2), Msx2, or osterix, and the loss of endogenous inhibitors of mineralization, such as matrix γ-carboxyglutamic acid protein and fetuin. 5 Bone morphogenetic proteins (BMPs) are members of the transforming growth factor β family and were originally identified by their capacity to induce ectopic bone formation. 6, 7 BMPs play a role in the differentiation of VSMCs and in determining the phenotypic profile of osteoblasts and chondroblasts. 8 Increased BMP signaling activity promotes vascular calcification, and increased expression of BMP ligands has been detected in calcified vascular lesions in patients with diabetes mellitus or chronic kidney disease. [9] [10] [11] Among >20 BMP ligands identified to date, BMP2 was shown to inhibit VSMC proliferation and drive both osteogenic and chondrogenic differentiation of mesenchymal stem cells. 12, 13 Binding of a BMP ligand to a specific type II receptor activates a type I receptor, resulting in the phosphorylation and nuclear translocation of SMADs 1, 5, and 8 (SMAD1/5/8), which act as transcription factors, promoting osteogenic gene expression. 14 In a recent study, pharmacological inhibition of BMP signaling inhibited atheroma development and vascular calcification in high fat diet-fed low-density lipoprotein receptor −/− mice, suggesting a potential benefit of BMP inhibition in the treatment of vascular calcification. 8 The development of novel agents against these targets with the capacity to modulate signaling pathways would be beneficial for the treatment of patients with atherosclerosis and vascular calcification.
Estrogen-related receptors (ERRs) are closely related to estrogen receptors, sharing high homology in the DNAbinding domain, although they do not bind estrogen. 15 The estrogen receptor-related receptor subfamily consists of 3 members, ERRα, ERRβ, and ERRγ (NR3B1-3), which bind to classic estrogen response elements and to extended halfsite core sequences (TNAAGGTCA; ERR response element [ERRE]) as either monomers or dimers. 16 ERRα is strongly expressed throughout osteoblast differentiation and regulates osteopontin expression through a noncanonical ERRα response element. 17, 18 Previously, we reported that ERRγ is expressed in osteoblast progenitors and negatively regulates BMP2-induced osteoblast differentiation and bone formation. 19 However, the role of ERRγ in vascular calcification remains to be determined.
The aim of the present study was to clarify the role of ERRγ in vascular calcification. The expression of ERRγ and the involvement of the BMP2 signaling pathway were examined during the process of vascular calcification. The effect of inhibition of endogenous ERRγ expression by siRNA or the ERRγ inhibitor GSK5182 on vascular calcification was examined in vitro and in vivo.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement. 
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Results
ERRγ Expression Is Increased in VSMCs by Calcification Medium
To induce VSMC calcification, cells were cultured in calcification medium (CM) for 5 days. CM-induced VSMC calcification was confirmed by morphological changes (nodule formation) and increased extracellular calcium deposits in VSMCs, as determined by von Kossa staining and quantification of calcium content ( Figure 1A and 1B). During the process of VSMC calcification, the mRNA and protein levels of ERRγ increased progressively compared with those of the control ( Figure 1C and 1D). These data indicate that the induction of ERRγ expression during VSMC calcification may play a role in the calcification process.
Overexpression of ERRγ in VSMCs Induces Osteogenic Gene Expression Via Upregulation of BMP2 Signaling
To determine the role of ERRγ upregulation in the process of VSMC calcification, the effects of adenovirus-mediated overexpression of ERRγ (Ad-ERRγ) on osteogenic gene expression were examined. The results of semiquantitative reverse transcriptase polymerase chain reaction showed that Ad-ERRγ dose-dependently upregulated the expression of osteogenic genes, including Bmp2, Runx2, Spp1, Msx2, and Bglap, and downregulated the expression of Acta2 ( 
ERRγ Increases BMP2 Promoter Activity Through Both Direct Binding to its Response Elements and Indirect Binding to CREB Binding Elements
To identify the ERRγ binding site on the Bmp2 promoter, we constructed 2 Bmp2 reporter gene promoters containing putative ERRE1 (put-ERRE1) and put-ERRE2 with serial 5′ deletions, namely D1 (−775 to +165 bp) and D2 (−195 to +165 bp; Figure 3A , upper panel). A transient transfection assay in C2C12 cells showed that the activity of the wild-type Bmp2 promoter (−2712 to +165 bp) was increased by ≈5-fold by ERRγ. Deletion of put-ERRE2 (D1 construct) did not decrease ERRγ-stimulated Bmp2 promoter luciferase activity, whereas removal of both put-ERRE1 and put-ERRE2 (D2 construct) markedly attenuated the ERRγ stimulation of reporter activity ( Figure 3A , lower), indicating that put-ERRE1 is essential for ERRγ binding. To further examine the binding of ERRγ to put-ERRE1 on the Bmp2 promoter, we performed a ChIP assay in C2C12 cells. The results showed that ERRγ binds to put-ERRE1 ( Figure 3B ). Moreover, a direct interaction between ERRγ and ERRE1 but not ERRE2 was confirmed by electrophoretic mobility shift assay analysis ( Figure 3C and Figure  II in the online-only Data Supplement). A mutagenesis study showed that mutation of put-ERRE1 markedly attenuated the effect of ERRγ on Bmp2 promoter activity ( Figure 3D ). However, ERRγ-induced Bmp2 promoter activation was still detected after deletion of 2 put-ERRE motifs or mutation of put-ERRE1, suggesting that an indirect mechanism may contribute to promoter stimulation by ERRγ. CREB is known to transacitvate BMP2 through CRE in the BMP2 promoter, 20 and we found a putative CREB-binding site on D2 −195 BMP2 promoter. Therefore, we checked whether CRE contributes to ERRγ-stimulated BMP2 promoter activation after deletion of both ERRE1 and ERRE2. The results showed that when the CRE of the D2-195 BMP2 promoter was mutated, ERRγ no longer stimulated BMP2 promoter activity, whereas it stimulated the wild-type CRE control ( Figure 3E ).
Knockdown of ERRγ Attenuates VSMC Calcification
Our results showing that ERRγ expression is induced during VSMC calcification and ERRγ overexpression promotes osteogenic gene expression led us to investigate the effect of siRNA-mediated ERRγ silencing on CM-induced VSMC calcification. As shown in Figure 4A and 4B, inhibition of endogenous ERRγ expression by siRNA prevented CM-induced upregulation of osteogenic genes, such as Bmp2, Runx2, Spp1, Msx2, and Bglap, and phosphorylation of SMAD1/5/8. Von Kossa staining showed that VSMC calcification induced by CM was markedly attenuated by siRNA silencing of ERRγ and that the attenuation could be rescued by overexpression of ERRγ ( Figure 4C ). Quantification of calcium levels revealed that siERRγ decreased calcium deposition, which was rescued by overexpression of ERRγ ( Figure 4D ). Taken together, these data indicate that ERRγ has a pivotal role in CM-induced vascular calcification.
Pharmacological Inhibition of ERRγ Activity Attenuates VSMC Calcification
We next evaluated whether inhibition of ERRγ activity by its inverse agonist, GSK5182, could prevent vascular calcification. Consistent with the results of ERRγ siRNA, GSK5182 downregulated osteogenic marker gene expression in a dose-dependent manner and upregulated Acta2 expression ( Figure 5A ). GSK5182 inhibited CM-induced phosphorylation of SMAD1/5/8, as shown by Western blotting (Figure 5B) , and successfully prevented CM-induced VSMC calcification ( Figure 5C and 5D) . The inhibition of ERRγ activity by GSK5182 was confirmed by transient transfection with a Bmp2 promoter luciferase reporter plasmid ( Figure 5E ).
GSK5182 Prevents Vascular Calcification Ex Vivo and In Vivo
To examine the inhibitory effect of GSK5182 on calcification ex vivo, mouse abdominal aorta was cut into rings and cultured in vitro with CM. Consistent with previous results, Von Kossa staining and immunohistochemical staining for BMP2 showed that GSK5182 significantly inhibited CM-induced VSMC calcification and calcium deposition and downregulated BMP2 expression ( Figure 6A-6C) . The effect of GSK5182-mediated ERRγ inhibition on vascular calcification was examined in vivo using an established vascular calcification animal model, in which mice are injected subcutaneously with high doses of cholecalciferol (Vit-D 3 ) for 3 consecutive days. Daily intraperitoneal injection of GSK5182 (10 mg/kg/d) significantly attenuated vascular calcification in the aorta and decreased calcium deposition ( Figure 6D and 6E).
Discussion
The results of the present study showed that ERRγ expression was induced during the process of vascular calcification, and overexpression of ERRγ upregulated BMP2 transcription, leading to activation of downstream signaling. Moreover, siRNA-mediated knockdown of endogenous ERRγ or inhibition of ERRγ activity by the selective inverse agonist GSK5182 attenuated vascular calcification by downregulating osteogenic gene expression and decreasing calcium deposition in vitro and in vivo.
A growing body of evidence suggests that ERRγ is relevant to vascular pathophysiology, including angiogenesis and restoration of blood perfusion in ischemic tissues. 21, 22 Here, we provide another pathophysiological function for ERRγ in the process of vascular calcification. Because a previous study reported that ERRγ negatively regulates BMP2-induced osteoblast differentiation and bone formation, we initiated this study with the expectation that ERRγ would have beneficial effects on vascular calcification under calcificationprone conditions. However, the results showed the ERRγ has opposite roles in mineralization between VSMCs and osteoblasts. Upregulation of ERRγ expression during vascular calcification promoted dedifferentiation of VSMCs to an osteogenic phenotype and exacerbated CM-induced calcification through upregulation of BMP2 expression. However, we did not observe induction of vascular calcification after ERRγ overexpression under normal phosphate conditions, indicating that the action of ERRγ on vascular calcification requires calcification-prone conditions.
ERRγ induced BMP2 transcription via direct binding to its response element in the BMP2 promoter and indirect induction of CREB, as shown by electrophoretic mobility shift assay and mutagenesis of promoter-reporter assay. BMP2 regulates osteoblast differentiation and bone formation through the induction of osteogenic transcription factors, such as Runx2 and Msx2. 23 Runx2 regulates the transcription of genes associated with osteoblast differentiation, endochondral bone formation, and neovascularization, and Msx2 is a critical regulator of intramembranous bone formation. [24] [25] [26] [27] BMP2 signaling is mainly mediated by SMAD1/5/8 phosphorylation and their modulation of target gene expression. 28 Phosphorylation of SMAD1/5/8 and their subsequent nuclear translocation are critical steps in BMP2 signaling, 29 and our results showed that Ad-ERRγ promoted the phosphorylation of SMAD1/5/8 via BMP2 signaling and, consequently, upregulated BMP2 target genes, such as Runx2, Msx2, and Bglap.
Pharmacological BMP2 inhibition has received much attention because BMP2 signaling plays a key role in the regulation of vascular calcification. In a previous study, the BMP antagonist noggin blocked osteoblastic differentiation and mineralization in the presence of high phosphate. 30 Derwall et al reported that a small molecule BMP inhibitor or a recombinant BMP antagonist inhibited vascular calcification, atherosclerosis development, vascular inflammation, and atheroma development in atherogenic animals by suppressing the activation of SMAD1/5/8. 8 In line with the previous observations, we showed that pharmacological inhibition of ERRγ activity by its inverse agonist GSK5182 decreased BMP2 signaling and attenuated CM-induced VSMC calcification ex vivo. These protective findings were supported by results obtained in our high-dose vitamin D 3 -induced vascular calcification animal model. Taken together, our data indicate that GSK5182 may reduce the risk of cardiovascular morbidity and mortality by attenuating vascular calcification. However, because ERRγ had contrasting roles in mineralization between osteoblasts and VSMCs, 19 it will be necessary to elucidate the tissue-specific role of ERRγ before it can be used as a target in clinical applications.
To the best of our knowledge, the present study is the first to show that inhibition of ERRγ attenuates vascular calcification in vitro and in vivo. Our results suggest that ERRγ is a promising therapeutic target for the treatment of vascular calcification. The generation of ERRγ-specific inverse agonists, such as GSK5182, may have therapeutic applications in the prevention of vascular calcification. 
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(BCA) method (Pierce, Rockford, IL). Total calcium content was normalized to total protein content for each culture. For the determination of calcium contents ex vivo in aortic ring tissue, the sliced aortic ring tissues were decalcified with 0.6N HCl for 24 hours and calcium contents were determined according to the above procedure and normalized to the length (mm) of the sliced aorta. For determination of calcium contents of aortas in vivo, whole aorta tissues were washed with PBS and weighted. The whole aorta tissues were ground using the Precellys 24 tissue homogenizer (Bertin Technologies, Montigny-le-Bretonneux, France) with 0.6 N of HCl, followed by incubation at 4°C for 1 day. Calcium deposition was determined by colorimetric analysis using the QuantiChrom TM calcium assay kit and normalized to micrograms CA/mg wet weight.
Luciferase reporter assay and plasmid constructs
C2C12 and A7r5 cells were used for transient transfection assays. Transient transfection was performed using Mirus TransIT-LT1 transfection reagent (Mirus Bio LLC, Madison, WI, USA) and Lipofectamine 2000 (Invitrogen, Carlsbad, CA. USA) according to the manufacturers' protocols. The cells were then harvested 48 hours after transfection and luciferase activity was measured. Luciferase activity was normalized to β-galactosidase activity. The data are representative of at least three to five independent experiments. The pcDNA3 vector expressing Flag-ERR was described previously 2 . The reporter plasmid encoding BMP2-Luc (+165 to −2712) was kindly donated by Ming Zhao (Vanderbilt University, Nashville, USA). BMP2-Luc (+165 to −2712) was used as the template for generating truncation/point mutant constructs. Truncated mouse BMP2 promoter constructs were cloned with the following primers: BMP2(-775)-F, 5′-CTGGTACCGGCGGCGTCTCCTTTAAAAGC-3′; BMP2(-195)-F, 5′-CTGGTACCAGAGTCAGGCTGAGGGATGCA-3′; GLprimer2-R, 5′-CTTTATGTTTTTGGCGTCTTCCA-3′. Point mutation on the ERRE of the mouse BMP2 promoter was generated with the following primers: BMP2-pm-F, 5′-GAGCGCGATTTCACCCGGTTT-3′; BMP2-pm-R, 5′-AAACCGGGTGAAATCGCGCTC-3′.
A point mutation in the CRE of the mouse BMP2 promoter was generated with the following primers: BMP2-CREpm-F, 5′-TGAGGCCGGATCCAGCAGCAGCCTT-3′; BMP2-CREpm-R, 5′-AAGGCTGCTGCTGGATCCGGCCTCA-3′.
Chromatin immunoprecipitation (ChIP)
C2C12 cells were infected by Ad-Mock or Ad-ERR adenovirus and cross-linked with 1% PFA for 10 minutes. After sonication, soluble chromatin was immunoprecipitated by anti-Flag antibody (Santa Cruz Biotechnology). Collected DNA was purified using the SolGent PCR purification kit (SolGent, Daejeon, Korea) and PCR was performed using the following primers: non-binding-F, 5′-TCTCGCCTTCTGAACTGGCAGATA-3′; non-binding-R, 5′-TGGAAATGAGTGTAAACGCATGGG-3′; ERRE1-F, 5′-GTGGAGTGTTTTATTGCCGCCTT-3′; and ERRE1-R, 5′-CCAGTTTGCAAAGCAAAGACCGAG-3′.
